Argenx Se (ARGX) Profit After Tax Growth (3y) (2019 - 2026)
Argenx Se (ARGX) Profit After Tax Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 71.02% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 17.25% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.89% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 37.44% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -29.12% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 59.34% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -38.56% |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.87% |
| Mar 31, 2026 | 90.95% |
| Dec 31, 2025 | 127.53% |
| Sep 30, 2025 | 53.29% |
| Jun 30, 2025 | 43.22% |
| Mar 31, 2025 | 43.65% |
| Dec 31, 2024 | -30.04% |
| Sep 30, 2024 | 33.54% |
| Jun 30, 2024 | -28.96% |
| Mar 31, 2024 | -22.51% |
| Dec 31, 2023 | 32.34% |
| Sep 30, 2023 | 23.24% |
| Jun 30, 2023 | 36.15% |
| Mar 31, 2023 | 4.79% |
| Dec 31, 2022 | 45.73% |
| Sep 30, 2022 | -57.14% |
| Jun 30, 2022 | -48.74% |
| Mar 31, 2022 | -223.41% |
| Dec 31, 2021 | 108.80% |
| Sep 30, 2021 | -52.01% |